Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin.

Next Previous
Trial Profile

Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms POMOSCH
  • Sponsors Merck & Co; Merck Sharp & Dohme; Schering-Plough

Most Recent Events

  • 10 Jan 2012 Actual patient number (790) added as reported by ClinicalTrials.gov.
  • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 28 Jan 2011 Planned end date changed from Mar 2011 to Sep 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top